

FIV Vif (Vif1-3): sc-65658

BACKGROUND

Feline immunodeficiency virus (FIV) is a lentivirus that affects domestic cats throughout the world. Five subtypes of FIV exist based on amino acid sequence differences in the viral envelope. The main mode of FIV transmission is through deep bite wounds, though it can also be spread via mucosal surfaces such as those in the mouth, rectum and vagina. FIV is similar to Human Immunodeficiency Virus (HIV) in that it infects many cell types in its host, including CD4⁺ and CD8⁺ T lymphocytes, B lymphocytes and macrophages. FIV eventually leads to collapse of the immune system because of the infection and exhaustion of the CD4⁺ cells. FIV p120 and p24 are glycoproteins that localize to the envelope of the virus and are useful in diagnosis of the disease. The Vif protein localizes to the nucleus and is essential for efficient viral replication in many cell types.

REFERENCES

1. Pancino, G., Castelot, S. and Sonigo, P. 1995. Differences in feline immunodeficiency virus host cell range correlate with envelope fusogenic properties. *Virology* 206: 796-806.
2. Giannecchini, S., Di Fenza, A., D'Ursi, A.M., Matteucci, D., Rovero, P. and Bendinelli, M. 2003. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. *J. Virol.* 77: 3724-3733.
3. Lin, Y.C., Beck, Z., Morris, G.M., Olson, A.J. and Elder, J.H. 2003. Structural basis for distinctions between substrate and inhibitor specificities for feline immunodeficiency virus and human immunodeficiency virus proteases. *J. Virol.* 77: 6589-6600.
4. Shimojima, M., Nishimura, Y., Miyazawa, T., Tohya, Y. and Akashi, H. 2004. T cell subpopulations mediating inhibition of feline immunodeficiency virus replication in mucosally infected cats. *Microbes Infect.* 6: 265-271.
5. Reggeti, F. and Bienzle, D. 2004. Feline immunodeficiency virus subtypes A, B and C and intersubtype recombinants in Ontario, Canada. *J. Gen. Virol.* 85: 1843-1852.
6. Sinn, P.L., Burnight, E.R., Hickey, M.A., Blissard, G.W. and McCray, P.B. 2005. Persistent gene expression in mouse nasal epithelia following feline immunodeficiency virus-based vector gene transfer. *J. Virol.* 79: 12818-12827.
7. Dean, G.A., LaVoy, A., Yearley, J. and Stanton, C. 2006. Cytokine modulation of the innate immune response in feline immunodeficiency virus-infected cats. *J. Infect. Dis.* 193: 1520-1527.
8. Dunham, S.P., Bruce, J., MacKay, S., Golder, M., Jarrett, O. and Neil, J.C. 2006. Limited efficacy of an inactivated feline immunodeficiency virus vaccine. *Vet. Rec.* 158: 561-562.

SOURCE

FIV Vif (Vif1-3) is a mouse monoclonal antibody raised against FIV Vif.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PRODUCT

Each vial contains 100 µg IgG_{2a} in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

FIV Vif (Vif1-3) is recommended for detection of Vif of FIV origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and flow cytometry (1 µg per 1 x 10⁶ cells).

Molecular Weight of FIV Vif: 29 kDa.

STORAGE

Store at 4° C, ****DO NOT FREEZE****. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PROTOCOLS

See our web site at www.scbt.com for detailed protocols and support products.